CN106729212B - Compound traditional Chinese medicine composition for treating acute stage of gout and application thereof - Google Patents
Compound traditional Chinese medicine composition for treating acute stage of gout and application thereof Download PDFInfo
- Publication number
- CN106729212B CN106729212B CN201710022330.4A CN201710022330A CN106729212B CN 106729212 B CN106729212 B CN 106729212B CN 201710022330 A CN201710022330 A CN 201710022330A CN 106729212 B CN106729212 B CN 106729212B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- gout
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 201000005569 gout Diseases 0.000 title claims abstract description 54
- 230000001154 acute Effects 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 20
- 241000218176 Corydalis Species 0.000 claims abstract description 20
- 235000006533 astragalus Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 241000218691 Cupressaceae Species 0.000 claims description 13
- 241001523681 Dendrobium Species 0.000 claims description 13
- 241001573366 Astragalus membranaceus Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 abstract description 33
- 230000002522 swelling Effects 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 28
- 208000002193 Pain Diseases 0.000 abstract description 25
- 210000004369 Blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 230000001737 promoting Effects 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 13
- 230000001717 pathogenic Effects 0.000 abstract description 13
- 238000005728 strengthening Methods 0.000 abstract description 12
- 208000006820 Arthralgia Diseases 0.000 abstract description 11
- 208000004880 Polyuria Diseases 0.000 abstract description 11
- 230000035619 diuresis Effects 0.000 abstract description 11
- 230000025627 positive regulation of urine volume Effects 0.000 abstract description 11
- 210000004185 Liver Anatomy 0.000 abstract description 10
- 241001061264 Astragalus Species 0.000 abstract description 9
- 210000000952 Spleen Anatomy 0.000 abstract description 9
- 210000000456 talus bone Anatomy 0.000 abstract description 9
- 210000003734 Kidney Anatomy 0.000 abstract description 8
- 235000002723 Dioscorea alata Nutrition 0.000 abstract description 7
- 235000007056 Dioscorea composita Nutrition 0.000 abstract description 7
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 abstract description 7
- 235000005362 Dioscorea floribunda Nutrition 0.000 abstract description 7
- 235000004868 Dioscorea macrostachya Nutrition 0.000 abstract description 7
- 235000005361 Dioscorea nummularia Nutrition 0.000 abstract description 7
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 abstract description 7
- 240000005760 Dioscorea villosa Species 0.000 abstract description 7
- 235000006350 apichu Nutrition 0.000 abstract description 7
- 235000009508 confectionery Nutrition 0.000 abstract description 7
- 235000004879 dioscorea Nutrition 0.000 abstract description 7
- 241000721047 Danaus plexippus Species 0.000 abstract description 6
- 241000208966 Polygala Species 0.000 abstract description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 241000427159 Achyranthes Species 0.000 abstract description 4
- 210000001124 Body Fluids Anatomy 0.000 abstract description 4
- 241000972673 Phellodendron amurense Species 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 240000004638 Dendrobium nobile Species 0.000 abstract description 3
- 241000972672 Phellodendron Species 0.000 abstract description 3
- 241001404789 Smilax glabra Species 0.000 abstract description 3
- 240000009022 Smilax rotundifolia Species 0.000 abstract description 3
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract description 3
- 230000000240 adjuvant Effects 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 240000000031 Achyranthes bidentata Species 0.000 abstract description 2
- 206010042674 Swelling Diseases 0.000 description 24
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 10
- 210000002216 Heart Anatomy 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 210000001503 Joints Anatomy 0.000 description 6
- 210000002784 Stomach Anatomy 0.000 description 6
- 229940116269 Uric Acid Drugs 0.000 description 6
- 102000025380 C-Reactive Protein Human genes 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 210000002700 Urine Anatomy 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 210000004072 Lung Anatomy 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 210000001624 Hip Anatomy 0.000 description 3
- 210000003127 Knee Anatomy 0.000 description 3
- 210000000214 Mouth Anatomy 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 231100000765 Toxin Toxicity 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000001575 pathological Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 201000010874 syndrome Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 208000001848 Dysentery Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 210000003414 Extremities Anatomy 0.000 description 2
- 206010016286 Febrile disease Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 210000002683 Foot Anatomy 0.000 description 2
- 210000000878 Metatarsophalangeal Joint Anatomy 0.000 description 2
- 210000002850 Nasal Mucosa Anatomy 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001250596 Pleione Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- 201000008286 diarrhea Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940107666 ASTRAGALUS ROOT Drugs 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 241000031023 Amana edulis Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010001954 Amnestic disease Diseases 0.000 description 1
- 206010002156 Anal fistula Diseases 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 206010003549 Asthenia Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000000350 Central Nervous System Disease Diseases 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000002573 Connective Tissue Disease Diseases 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 206010013781 Dry mouth Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018836 Haematochezia Diseases 0.000 description 1
- 208000006750 Hematuria Diseases 0.000 description 1
- 208000002287 Hemorrhoids Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020937 Hypoaesthesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000009883 Joint Disease Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 206010027327 Menstrual disease Diseases 0.000 description 1
- 208000008763 Mercury Poisoning Diseases 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 206010036067 Polydipsia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 210000004915 Pus Anatomy 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 208000005687 Scabies Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000059156 Toddalia Species 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 201000009230 common cold Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000032686 female pregnancy Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 201000001431 hyperuricemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 239000009910 sargent gloryvine Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
Abstract
The invention discloses a compound traditional Chinese medicine composition for treating acute stage of gout, which comprises the following raw materials of astragalus, roasted polygala tenuifolia, dendrobe, achyranthes bidentata, honeysuckle, rhizoma atractylodis, phellodendron, yam rhizome, glabrous greenbrier rhizome and corydalis tuber according to parts by weight, wherein the astragalus is reused in the formula, and the compound traditional Chinese medicine composition can be used for assisting vital qi to directly reach a disease site by using various medicines, eliminating evil and expelling stagnation as a monarch medicine; the dendrobium nobile is sweet and light in taste and cold in nature, and has the effects of nourishing yin, promoting the production of body fluid and clearing heat so as to help monarch drugs; smilax glabra and phellodendron bark, rhizoma Smilacis Glabrae are cold in nature and warm in nature, bitter in nature and dry dampness, and good at removing damp-heat in the lower energizer; rhizoma Dioscoreae Septemlobae and rhizoma Atractylodis have effects of invigorating spleen, eliminating dampness, and eliminating arthralgia, and are used as ministerial drugs; honeysuckle flower detoxifies and subsides swelling, corydalis tuber removes blood stasis and subsides swelling, and roasted polygala root dispels phlegm and subsides swelling and relieves swelling and pain together as adjuvant drugs; achyranthes root, radix Achyranthis bidentatae has the effects of promoting blood circulation, dredging channels and collaterals, nourishing liver and kidney, and guiding drugs to act as channel-guiding drugs; the traditional Chinese medicine composition has the effects of strengthening body resistance and eliminating pathogenic factors, clearing heat and promoting diuresis, and relieving swelling and pain, has the functions of strengthening body resistance and eliminating pathogenic factors, clearing heat and promoting diuresis, and relieving swelling and pain, and is a safe and effective pure traditional Chinese medicine preparation for treating both symptoms and root causes.
Description
Technical Field
The invention relates to a compound traditional Chinese medicine, in particular to a compound traditional Chinese medicine composition for treating acute stage of gout and application thereof.
Background
Gout is a joint disease caused by urate deposition, and is directly related to hyperuricemia caused by purine metabolic disorder and/or reduced uric acid excretion. Acute stage of gout is mainly manifested by redness, heat, swelling and severe pain of abrupt joints and surrounding soft tissues as main clinical manifestations. The prevalence rate of China is about 0.34-2.84%, which is obviously higher than that of the prior art. Colchicine is usually used for treating gout in the acute stage, and clinical application is limited due to serious gastrointestinal side effects, so that a safe and effective method for treating gout in the acute stage is expected by clinicians.
According to the symptoms and signs of gout in the acute stage, traditional Chinese medicine belongs to the category of "heat arthralgia". The pathogenesis of the gout is that pathological products such as deficiency of vital qi, dysfunction of spleen and kidney, damp-heat phlegm stasis and the like gather in the body, the pathological products are retained in channels and collaterals, the pathological products are damaged by overeating and seven emotions, the patients feel exogenous pathogenic factors, combine internal and external pathogenic factors, the qi and blood are stagnated and obstructed, damp turbidity flows into joints, gout is generated, and the symptoms such as red, swelling, heat, pain and the like appear. Therefore, strengthening body resistance to eliminate pathogenic factors, clearing heat and promoting diuresis, and relieving swelling and pain are basic treatment methods for gout in acute stage.
In the prior art, a Chinese patent database discloses a plurality of compound traditional Chinese medicines (such as CN201310737037.8, CN201410150392.X, CN201310723249.0, CN201310642949.7, CN200510039040.8 and the like) for treating gout, and the medicines disclosed by the patents all take the main formula principles of clearing heat, promoting diuresis, relieving swelling and pain as well as strengthening body resistance, so that the medicines have little effect; and no Chinese patent medicine aiming at the acute stage of gout exists in the current market.
Therefore, aiming at the defects and shortcomings in the prior art, the invention provides a compound traditional Chinese medicine for treating gout in an acute stage, so that the compound traditional Chinese medicine has the effects of strengthening body resistance and eliminating evil, clearing heat and promoting diuresis, and relieving swelling and pain, and is a safe and effective pure traditional Chinese medicine preparation for treating both symptoms and root causes.
Disclosure of Invention
In view of the above, the invention aims to provide a compound traditional Chinese medicine composition for treating gout in the acute stage and application thereof, which have the effects of strengthening body resistance and eliminating pathogenic factors, clearing heat and promoting diuresis, and reducing swelling and relieving pain, and are a safe and effective pure traditional Chinese medicine preparation for treating both symptoms and root causes.
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
30-60 parts of astragalus membranaceus, 5-15 parts of roasted polygala tenuifolia, 15-30 parts of dendrobium, 10-20 parts of radix achyranthis bidentatae, 5-15 parts of honeysuckle, 5-15 parts of rhizoma atractylodis, 5-15 parts of golden cypress, 10-30 parts of yam rhizome, 10-30 parts of rhizoma smilacis glabrae and 10-30 parts of rhizoma corydalis;
further, the composition comprises the following raw materials in parts by weight:
40-60 parts of astragalus membranaceus, 8-13 parts of roasted polygala tenuifolia, 18-25 parts of dendrobium, 13-17 parts of radix achyranthis bidentatae, 8-13 parts of honeysuckle, 8-13 parts of rhizoma atractylodis, 8-13 parts of golden cypress, 18-25 parts of rhizoma dioscoreae hypoglaucae, 20-30 parts of rhizoma smilacis glabrae and 15-25 parts of rhizoma corydalis;
further, the composition comprises the following raw materials in parts by weight:
50 parts of astragalus membranaceus, 10 parts of roasted polygala tenuifolia, 20 parts of dendrobium, 15 parts of radix achyranthis bidentatae, 10 parts of honeysuckle, 10 parts of rhizoma atractylodis, 10 parts of golden cypress, 22 parts of rhizoma dioscoreae hypoglaucae, 25 parts of rhizoma smilacis glabrae and 20 parts of rhizoma corydalis;
further, one or more traditional Chinese medicines for improving or treating concurrent symptoms can be added;
furthermore, a preparation prepared by adding a pharmaceutically acceptable drug carrier can be added.
The invention also discloses application of the compound traditional Chinese medicine composition for treating the acute stage of gout in preparing a medicine for treating the acute stage of gout.
The invention has the beneficial effects that: the compound traditional Chinese medicine composition for treating the acute stage of gout fully considers the compatibility principle of traditional Chinese medicines aiming at the basic pathogenesis of the acute stage of gout, wherein astragalus is used in the formula, the astragalus is used for assisting vital qi to directly lead the medicines to the disease focus, pathogenic factors are eliminated, arthralgia is removed, and stagnation is removed to be monarch medicine; the dendrobium nobile is sweet and light in taste and cold in nature, and has the effects of nourishing yin, promoting the production of body fluid and clearing heat so as to help monarch drugs; smilax glabra and phellodendron bark, rhizoma Smilacis Glabrae are cold in nature and warm in nature, bitter in nature and dry dampness, and good at removing damp-heat in the lower energizer; rhizoma Dioscoreae Septemlobae and rhizoma Atractylodis are used as ministerial drugs for invigorating spleen, eliminating dampness and eliminating arthralgia. Honeysuckle flower, flos Lonicerae, rhizoma corydalis, blood stasis and swelling, and radix Polygalae, processed with herbs of dispelling phlegm and relieving swelling, together with swelling-resolving and pain-relieving, are used as adjuvant drugs. Achyranthes root, radix Achyranthis bidentatae has the effects of promoting blood circulation, dredging channels and collaterals, nourishing liver and kidney, and guiding drugs to the lower part to act as channel-guiding drugs. The medicines are combined to play the effects of strengthening vital qi to eliminate pathogenic factors, clearing heat and promoting diuresis, and reducing swelling and relieving pain. Clinically, the invention can obviously improve the symptoms of red, swollen, hot and painful symptoms of gout patients, promote the recovery of joint function, has the functions of strengthening body resistance and eliminating evil, clearing heat and promoting diuresis, and reducing swelling and relieving pain, and is a safe and effective pure Chinese medicinal preparation for treating both symptoms and root causes.
Astragalus root: sweet and warm, entering lung and spleen meridians, invigorating qi, consolidating superficial resistance, expelling pus, inducing diuresis, and promoting granulation. Can be used for treating deficiency of vital energy, asthenia, chronic diarrhea, proctoptosis, spontaneous perspiration, edema, prolapse of nasal mucosa and nasal mucosa, chronic nephritis, albuminuria, diabetes, and unhealed wound.
Polygala root: warm in nature, bitter and pungent in taste, has effects of tranquilizing mind, improving intelligence, eliminating phlegm, and relieving swelling, and can be used for treating insomnia, dreaminess, amnesia, palpitation, absentmindedness, expectoration, pyocutaneous disease, toxic swelling, and breast swelling and pain caused by imbalance between heart-yang and kidney-yin.
Dendrobe: sweet, light and slightly salty in nature and cold in nature, enter stomach, kidney and lung meridians, promote the production of body fluid, nourish stomach, clear heat and nourish yin. It is indicated for dry mouth with polydipsia due to fluid damage by febrile disease, and deficiency heat after illness, yin damaging dark eyes.
Achyranthes bidentata: ku Su acid and Ping enter heart, liver and large intestine meridians, and are good at tonifying liver and kidney, strengthening waist and knees, promoting blood circulation and drawing blood downward. It can be used for treating arthralgia due to cold-dampness, spasm of limbs, gonalgia, blood and qi circulation, and impairment of pathogenic heat and fire.
Honeysuckle flower: is cold in nature and sweet in taste, enters lung, heart and stomach meridians, has the efficacy of clearing heat and removing toxicity, and is mainly used for treating epidemic febrile disease, fever, heat toxin, bloody dysentery, carbuncle and ulcer, pyogenic infections, scrofula and anal fistula.
Rhizoma atractylodis: pungent and bitter in taste, warm in nature, entering spleen, stomach and liver channels, eliminating dampness and strengthening spleen, dispelling pathogenic wind and cold, improving eyesight, and can be used for treating damp obstruction of middle warmer, abdominal distention, diarrhea, edema, tinea pedis, cramped, rheumatalgia, wind-cold type common cold, night blindness, dim eyesight and astringent.
Phellodendron bark: bitter in taste and cold in nature, entering kidney and bladder meridians. Clearing heat, eliminating dampness, purging pathogenic fire, removing toxic substances, and eliminating dampness. It is used to treat dysentery due to heat, diarrhea, diabetes, jaundice, stranguria with turbid urine, hemorrhoid, hematochezia, leucorrhea with white discharge, hectic fever due to yin-deficiency, conjunctival congestion, swelling and pain, aphtha of the mouth and tongue, and pyocutaneous disease.
Rhizoma Dioscoreae Septemlobae: bitter and neutral, entering liver meridian, stomach meridian and bladder meridian. Dispel wind, promote diuresis. It is indicated for stubborn arthralgia due to wind-damp, pain in waist and knees, difficult urination, stranguria with turbid urine, spermatorrhea, damp-heat and sore-toxin.
Glabrous greenbrier rhizome: sweet and bland, neutral, mild, liver, stomach and spleen meridians, removing dampness, removing toxicity and easing joint movement. Can be used for treating damp-heat stranguria with turbid discharge, leukorrhagia, carbuncle swelling, scrofula, scabies, tinea, syphilis and limb spasm and arthralgia and myalgia caused by mercury poisoning.
Rhizoma corydalis: pungent, bitter and warm, entering liver and spleen meridians, promoting blood circulation, dissipating blood stasis, regulating qi-flowing for alleviating pain. It is used to treat pain of heart, abdomen, waist and knee, menoxenia, metrorrhagia, puerperal dizziness, lochiorrhea, and traumatic injury.
Detailed Description
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
30-60 parts of astragalus membranaceus, 5-15 parts of roasted polygala tenuifolia, 15-30 parts of dendrobium, 10-20 parts of radix achyranthis bidentatae, 5-15 parts of honeysuckle, 5-15 parts of rhizoma atractylodis, 5-15 parts of golden cypress, 10-30 parts of yam rhizome, 10-30 parts of rhizoma smilacis glabrae and 10-30 parts of rhizoma corydalis; in the formula, astragalus is used for strengthening healthy qi to directly lead the medicines to the disease focus, eliminate pathogenic factors and eliminate arthralgia and stagnation as monarch medicines; the dendrobium nobile is sweet and light in taste and cold in nature, and has the effects of nourishing yin, promoting the production of body fluid and clearing heat so as to help monarch drugs; smilax glabra and phellodendron bark, rhizoma Smilacis Glabrae are cold in nature and warm in nature, bitter in nature and dry dampness, and good at removing damp-heat in the lower energizer; rhizoma Dioscoreae Septemlobae and rhizoma Atractylodis are used as ministerial drugs for invigorating spleen, eliminating dampness and eliminating arthralgia. Honeysuckle flower, flos Lonicerae, rhizoma corydalis, blood stasis and swelling, and radix Polygalae, processed with herbs of dispelling phlegm and relieving swelling, together with swelling-resolving and pain-relieving, are used as adjuvant drugs. Achyranthes root, radix Achyranthis bidentatae has the effects of promoting blood circulation, dredging channels and collaterals, nourishing liver and kidney, and guiding drugs to the lower part to act as channel-guiding drugs. The medicines are combined to play the effects of strengthening vital qi to eliminate pathogenic factors, clearing heat and promoting diuresis, and reducing swelling and relieving pain.
In the embodiment, the raw materials of the composition comprise the following components in parts by weight:
40-60 parts of astragalus membranaceus, 8-13 parts of roasted polygala tenuifolia, 18-25 parts of dendrobium, 13-17 parts of radix achyranthis bidentatae, 8-13 parts of honeysuckle, 8-13 parts of rhizoma atractylodis, 8-13 parts of golden cypress, 18-25 parts of rhizoma dioscoreae hypoglaucae, 20-30 parts of rhizoma smilacis glabrae and 15-25 parts of rhizoma corydalis; the dosage is marked by the potency of the drug, although the composition of the prescription is the same, the dosage of the drug is different, and the potency of the drug is divided into different magnitudes. The mechanism of the formula is complex, the components generate synergistic effect by compatibility, the clinical curative effect is directly influenced, and the full formula dose is skillfully combined to generate unique curative effect, which is proper and not necessary. The efficacy of this example is significant.
In the embodiment, the raw materials of the composition comprise the following components in parts by weight:
50 parts of astragalus membranaceus, 10 parts of roasted polygala tenuifolia, 20 parts of dendrobium, 15 parts of radix achyranthis bidentatae, 10 parts of honeysuckle, 10 parts of rhizoma atractylodis, 10 parts of golden cypress, 22 parts of rhizoma dioscoreae hypoglaucae, 25 parts of rhizoma smilacis glabrae and 20 parts of rhizoma corydalis; the efficacy of this example is the best.
In this embodiment, one or more traditional Chinese medicines for ameliorating or treating concurrent symptoms may be added; gypsum Fibrosum and rhizoma anemarrhenae can be added for clearing heat and purging fire for fever and thirst; radix Isatidis, Pseudobulbus Cremastrae seu pleiones, etc. can be added to relieve swelling and pain; fructus Gardeniae preparata and Bulbus Lilii can be added to relieve restlessness and heart fire. In addition, the edible tulip and the paniculate swallowwort root can be added to obviously reduce the level of hematuria acid and improve the blood viscosity, and the sargentgloryvine stem and the asiatic toddalia root play the effects of removing damp-heat, clearing away heat and toxic materials, dredging collaterals, relieving swelling and pain, relieving gout caused by damp-heat toxin and eliminating symptoms such as arthralgia, numbness of limbs, red swelling and deformation of joints and the like caused by the fact that the damp-heat toxin is accumulated in the veins of the joints, so that the effects of activating collaterals, dredging collaterals and relieving pain are achieved.
In this embodiment, a formulation made with a pharmaceutically acceptable pharmaceutical carrier may be added. For example, the medicament carrier can be prepared into granules, oral liquid, tablets, capsules, pills and other forms by adopting the existing industrial production process.
The invention also discloses application of the compound traditional Chinese medicine composition for treating the acute stage of gout in preparing a medicine for treating the acute stage of gout, and the compound traditional Chinese medicine composition can be used for preparing the medicine for treating gout by adopting any method in the prior art and adding any other components.
The invention is further illustrated by the following specific examples.
Example one
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
30 parts of astragalus membranaceus, 5 parts of roasted polygala tenuifolia, 15 parts of dendrobium, 10 parts of radix achyranthis bidentatae, 5 parts of honeysuckle, 5 parts of rhizoma atractylodis, 5 parts of golden cypress, 10 parts of rhizoma dioscoreae hypoglaucae, 10 parts of rhizoma smilacis glabrae and 10 parts of rhizoma corydalis.
Example two
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
60 parts of astragalus membranaceus, 15 parts of roasted polygala tenuifolia, 20 parts of dendrobe, 20 parts of radix achyranthis bidentatae, 10 parts of honeysuckle, 15 parts of rhizoma atractylodis, 15 parts of golden cypress, 30 parts of rhizoma dioscoreae hypoglaucae, 30 parts of rhizoma smilacis glabrae and 30 parts of rhizoma corydalis.
EXAMPLE III
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
40 parts of astragalus, 8 parts of roasted polygala root, 18 parts of dendrobium, 13 parts of radix achyranthis bidentatae, 8 parts of honeysuckle, 8 parts of rhizoma atractylodis, 8 parts of golden cypress, 18 parts of yam rhizome, 20 parts of rhizoma smilacis glabrae and 15 parts of rhizoma corydalis.
Example four
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
60 parts of astragalus, 13 parts of roasted polygala root, 25 parts of dendrobium, 17 parts of radix achyranthis bidentatae, 13 parts of honeysuckle, 13 parts of rhizoma atractylodis, 13 parts of golden cypress, 25 parts of yam rhizome, 30 parts of rhizoma smilacis glabrae and 25 parts of rhizoma corydalis.
EXAMPLE five
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
30 parts of astragalus, 13 parts of roasted polygala root, 15 parts of dendrobium, 13 parts of radix achyranthis bidentatae, 15 parts of honeysuckle, 13 parts of rhizoma atractylodis, 5 parts of phellodendron, 25 parts of yam rhizome, 30 parts of rhizoma smilacis glabrae and 15 parts of rhizoma corydalis.
EXAMPLE six
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
50 parts of astragalus membranaceus, 10 parts of roasted polygala tenuifolia, 20 parts of dendrobium, 15 parts of radix achyranthis bidentatae, 10 parts of honeysuckle, 10 parts of rhizoma atractylodis, 10 parts of golden cypress, 22 parts of rhizoma dioscoreae hypoglaucae, 25 parts of rhizoma smilacis glabrae and 20 parts of rhizoma corydalis.
EXAMPLE seven
The compound traditional Chinese medicine composition for treating acute stage of gout comprises the following raw materials in parts by weight:
60 parts of astragalus, 15 parts of roasted polygala root, 30 parts of dendrobium, 20 parts of achyranthes root, 15 parts of honeysuckle, 15 parts of rhizoma atractylodis, 15 parts of phellodendron, 30 parts of yam rhizome, 30 parts of glabrous greenbrier rhizome and 30 parts of corydalis tuber.
The following are the clinical research conditions of the traditional Chinese medicine composition, which show the effect of the traditional Chinese medicine composition in treating acute gout:
general conditions
72 patients in the acute stage of gout are clinically selected, wherein the patients are 18-65 years old, 46.44 +/-12.22 years old on average, 0.5-3.5 days in course of disease and 1.88 +/-1.95 days on average.
Diagnostic criteria
See 1977 for the American Association of rheumatology standards.
Specific urate crystals were found in synovial fluid: or the tophus is verified to contain sodium urate crystals by chemical method or polarized light microscope examination: or 6 of the following 12 clinical manifestations, laboratory examinations and X-ray signs:
1) inclusion case criteria
Voluntarily as a subject; the age is 18-65 years old, and the patients meet the gout acute stage diagnosis standard within 48 hours after the onset of disease.
2) Exclusion criteria
Chronic diffuse connective tissue disease. ② stopping using uric acid-reducing medicine (such as allopurin) or other Chinese medicine to reduce uric acid for less than 2 weeks. ③ pregnant, preparatory to gestation and lactating women. Fourthly, the liver disease is in the active period or abnormal liver function, and the kidney function is damaged; combined with heart, lung, central nervous system diseases or malignant tumors; psychosis; blood routine: WBC or Hb or PLT are below the normal value, or with other blood system disorders; or mental disability does not properly describe the person who feels himself. Five active peptic ulcers exist in nearly one year. Sixthly, the patient with alcoholism, drug addiction or drug abusers. Seventhly, allergic constitution or allergy to various medicines.
Treatment regimens
The compound traditional Chinese medicine is decocted with water for oral administration; when the traditional Chinese medicine composition is decocted, one or more traditional Chinese medicines for improving or treating concurrent symptoms can be added according to different disease conditions under the condition that the effect of the traditional Chinese medicine composition is not influenced, and gypsum and rhizoma anemarrhenae are added for clearing heat and purging fire for fever and thirst; radix Isatidis, Pseudobulbus Cremastrae seu pleiones, etc. can be added to relieve swelling and pain; fructus Gardeniae preparata and Bulbus Lilii can be added to relieve restlessness and heart fire. 72 patients were randomized into 3 groups of 24 patients each, and one to three treatments were given to each of the examples for 7 days as a treatment course.
Observation indexes are as follows:
1) and (3) observation indexes are as follows:
red swelling and pain of joints, Chinese medicine symptoms and inflammatory index changes.
2) The curative effect standard is as follows: refer to the therapeutic effect judgment standard formulated in the clinical research guidelines of new Chinese medicine. Clinical remission: symptoms and signs disappear, main indexes (including blood sedimentation and C-reactive protein) detected in a laboratory are recovered or close to normal, and the total score is reduced by more than 95 percent compared with that before treatment; the effect is shown: the symptoms and physical signs basically disappear, the main indexes of laboratory examination are obviously improved, and the total score is reduced by < 95% but > 70% compared with that before treatment; the method has the following advantages: symptoms and signs are reduced, the main indexes of laboratory examination are improved, and the total score is reduced by < 70% but > 30% compared with the total score before treatment; and (4) invalidation: symptoms, signs and laboratory indices were not significantly improved, and the total score was reduced by < 30% compared to before treatment.
3) And (3) safety detection: the routine functions of blood, urine and stool and the functions of liver and kidney were recorded 1 time before and after the electrocardiographic treatment.
Results of the study
The effective rate of the clinical curative effect embodiment is 95.8 percent, and the control rate is 62.5 percent; the effective rate of the second embodiment is 100 percent, and the display control rate is 83.3 percent; the effective rate of the third embodiment is 95.8 percent, and the display control rate is 62.5 percent; the second embodiment of the invention is shown to be the best. Specific results are shown in table 1.
TABLE 1 Observation of clinical effects
The comparison between disease integral and Chinese medicine integral before and after treatment shows that P is less than 0.05 and has obvious difference. The redness, swelling, pain and heat of the joints are improved obviously, and the details are shown in a table 2.
TABLE 2 disease and syndrome score comparison
The blood sedimentation and C-reactive protein are obviously reduced (P is less than 0.05) before and after treatment, and the specific results are shown in Table 3.
TABLE 3 comparison of inflammation indices before and after treatment in two groups
The safety evaluation result is as follows: before and after treatment, all safety evaluation indexes have no change with statistical significance. In the treatment process, 1 case of epigastric discomfort and 1 case of rash appear, and the traditional Chinese medicine preparation can relieve the symptoms without special treatment.
The results show that: the traditional Chinese medicine compound has an obvious treatment effect on acute gout, has slight side effect and has higher clinical popularization value.
Examples of medical cases
Example 1: one certain piece, male, 63 years old. The patient has no obvious inducement to the occurrence of swelling and pain of the right instep for 2 days, burning sensation, red tongue with yellow and greasy coating and slippery pulse. The history of gout, routine (-) of blood and urine examination, slight rise of blood sedimentation and C-reactive protein, 578 mu mol/L of blood uric acid. And (3) diagnosis: in the acute stage of gout, syndrome differentiation of traditional Chinese medicine is as follows: accumulation of damp-heat. After the four treatments of the invention are given, the treatment is obviously relieved after 3 days, basically returns to normal after 5 days, and then the treatment for reducing uric acid is given.
Example 2: when a certain amount of ju is in age 45, a patient is diagnosed with red swelling of the first metatarsophalangeal joint of the left foot for 1 day, the pain of the patient suddenly attacks at night every year, the pain is severe and intolerable, and the curative effect of the self-taken anti-inflammatory analgesic is not obvious. The red and swollen metatarsophalangeal root is obvious, the mouth is dry, the mouth is bitter, the heart is restless, the tongue tip is red, the coating is yellow and thick, and the pulse is smooth. 765 mu mol/L of blood-looking uric acid, 38mm/h of blood sedimentation, 28mg/L of C-reactive protein and conventional (-) of blood and urine. And (3) diagnosis: in the acute stage of gout, syndrome differentiation of traditional Chinese medicine is as follows: accumulation of damp-heat. After the five treatments of the invention, complete remission can be achieved after 6 days of treatment, and blood uric acid is reviewed at 565 mu mol/L, and blood sedimentation and C-reactive protein (-) are examined.
Example 3: wei in men and 23 years old, gout attacks half a year repeatedly, and the disease is diagnosed after 1 day of aggravation. The patient is diagnosed with gout after the local hospital is perfected and examined half a year ago because the first metatarsophalangeal joint of the right foot is red and swollen after eating the hot pot, and is diagnosed with gout because the work is busy and the gout is not treated according to the standard treatment, and the patient is treated with aggravation after drinking because the unit has a dinner and the patient has a heavy load before 1 day. Diagnosis: a red tongue with yellow coating and a cracked tongue with a thready and rapid pulse. According to the medical history and the symptoms and signs, gout is diagnosed, damp-heat yin impairment is differentiated, and the six treatments are given to relieve symptoms after 5 days of treatment and cure after 2 days of consolidation.
Therefore, the traditional Chinese medicine composition has a definite curative effect on gout, is safe and effective in clinical application, and has unique advantages on gout acute stage.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (5)
1. A compound traditional Chinese medicine composition for treating acute stage of gout is characterized in that: the composition comprises the following raw materials in parts by weight: 30-60 parts of astragalus membranaceus, 5-15 parts of roasted polygala tenuifolia, 15-30 parts of dendrobe, 10-20 parts of radix achyranthis bidentatae, 5-15 parts of honeysuckle, 5-15 parts of rhizoma atractylodis, 5-15 parts of golden cypress, 10-30 parts of rhizoma dioscoreae hypoglaucae, 10-30 parts of rhizoma smilacis glabrae and 10-30 parts of rhizoma corydalis.
2. The compound traditional Chinese medicine composition for treating acute stage of gout according to claim 1, which is characterized in that: the composition comprises the following raw materials in parts by weight: 40-60 parts of astragalus membranaceus, 8-13 parts of roasted polygala tenuifolia, 18-25 parts of dendrobium, 13-17 parts of radix achyranthis bidentatae, 8-13 parts of honeysuckle, 8-13 parts of rhizoma atractylodis, 8-13 parts of golden cypress, 18-25 parts of rhizoma dioscoreae hypoglaucae, 20-30 parts of rhizoma smilacis glabrae and 15-25 parts of rhizoma corydalis.
3. The compound traditional Chinese medicine composition for treating acute stage of gout according to claim 1, which is characterized in that: one or more Chinese medicinal materials for improving or treating concurrent symptoms can be added.
4. The compound traditional Chinese medicine composition for treating acute stage of gout according to claim 1, which is characterized in that: can be made into preparations by adding pharmaceutically acceptable carriers.
5. The use of the compound traditional Chinese medicine composition for treating acute stage of gout according to any one of claims 1 to 4 in the preparation of a medicament for treating acute stage of gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710022330.4A CN106729212B (en) | 2017-01-12 | 2017-01-12 | Compound traditional Chinese medicine composition for treating acute stage of gout and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710022330.4A CN106729212B (en) | 2017-01-12 | 2017-01-12 | Compound traditional Chinese medicine composition for treating acute stage of gout and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106729212A CN106729212A (en) | 2017-05-31 |
| CN106729212B true CN106729212B (en) | 2021-01-26 |
Family
ID=58947933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710022330.4A Active CN106729212B (en) | 2017-01-12 | 2017-01-12 | Compound traditional Chinese medicine composition for treating acute stage of gout and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729212B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693936B (en) * | 2019-10-17 | 2022-04-01 | 上海长海医院 | Traditional Chinese medicine composition for reducing uric acid and preventing and treating hyperuricemia or gout and application thereof |
| CN111905053A (en) * | 2020-09-02 | 2020-11-10 | 许永雄 | Medicine for treating gout and preparation method thereof |
| CN112022966B (en) * | 2020-10-10 | 2022-03-08 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN113713060B (en) * | 2021-10-25 | 2022-07-05 | 陕西省中医医院 | Blood stasis removing and turbidity lowering prescription for treating gout |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114204A (en) * | 2010-10-28 | 2011-07-06 | 孔祥军 | Traditional Chinese medicine formula for treating gout |
| CN103705809A (en) * | 2013-12-23 | 2014-04-09 | 邵正荣 | Traditional Chinese medicine for curing gout |
-
2017
- 2017-01-12 CN CN201710022330.4A patent/CN106729212B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102114204A (en) * | 2010-10-28 | 2011-07-06 | 孔祥军 | Traditional Chinese medicine formula for treating gout |
| CN103705809A (en) * | 2013-12-23 | 2014-04-09 | 邵正荣 | Traditional Chinese medicine for curing gout |
Non-Patent Citations (1)
| Title |
|---|
| 清热化瘀泄浊通络法治疗急性痛风性关节炎54例;丁建华;《吉林中医药》;20081231;第28卷(第2期);第124页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106729212A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106729212B (en) | Compound traditional Chinese medicine composition for treating acute stage of gout and application thereof | |
| CN104258289A (en) | Traditional Chinese medicine for treating enteritis | |
| CN101574446A (en) | Chinese medicament for treating acute cystitis | |
| CN101745047A (en) | Chinese medicinal composition for treating gout disease and preparation method thereof | |
| CN101983644A (en) | Medicament for treating sequelae of apoplexy | |
| CN103479737A (en) | Traditional Chinese medicine composition for treating senile cutaneous pruritus and application thereof | |
| CN108619427B (en) | Pain-relieving and acid-reducing herb tea for preventing and treating gouty arthritis | |
| CN102872362A (en) | Traditional Chinese medicine for treating chronic cholecystitis | |
| CN1596943A (en) | Leech capsule | |
| CN102895572B (en) | Traditional Chinese medical composition for treatment of rheumatoid arthritis | |
| CN104645163A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN104740036A (en) | Traditional Chinese medicine composition for treating Qi stagnation and blood stasis amenorrhea | |
| CN103301373A (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN103520638B (en) | A kind of Traditional Chinese medicine compound composition for the treatment of prostate hyperplasia and preparation method thereof and application thereof | |
| CN113633748B (en) | Medicine for treating spontaneous bacterial peritonitis damp-heat stasis syndrome of liver cirrhosis and preparation method thereof | |
| CN106729213B (en) | Compound traditional Chinese medicine for treating rheumatoid arthritis in acute stage and application thereof | |
| CN112972559B (en) | Traditional Chinese medicine composition and traditional Chinese medicine mixture for treating bone and soft tissue suppurative inflammation | |
| CN106491780A (en) | A kind of treat Chinese medicine composition of gout and preparation method thereof | |
| CN110893206B (en) | Externally applied medicine for treating rheumatic arthritis and preparation method thereof | |
| CN102225130B (en) | Traditional Chinese medicine compound for treating rheumatoid arthritis and preparation method thereof | |
| CN105920292A (en) | Chinese medicinal composition for treating acute mastitis | |
| CN106266970B (en) | A kind of Chinese medicine composition treated production and cause endometritis | |
| CN105535793A (en) | Traditional Chinese medicinal composition for treating hemorrhoids | |
| CN104666824A (en) | Traditional Chinese medicinal composition for treating psoriasis | |
| CN105343707A (en) | Traditional Chinese medicine used for treating erythema annulare centrifugum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |